{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T18:00:05Z","timestamp":1790272805957,"version":"4.1.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T00:00:00Z","timestamp":1719273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T00:00:00Z","timestamp":1719273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the National Youth Top-notch Talent of Ten Thousand Talent Program","award":["2014-253"],"award-info":[{"award-number":["2014-253"]}]},{"name":"Translational Research Grant of HCRCH","award":["2020ZKMB06"],"award-info":[{"award-number":["2020ZKMB06"]}]},{"name":"Subtopic of National Basic Research Program of China","award":["2013CB966803"],"award-info":[{"award-number":["2013CB966803"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>High-grade B-cell lymphoma (HGBCL), the subtype of non-Hodgkin lymphoma, to be relapsed or refractory in patients after initial therapy or salvage chemotherapy. Dual dysregulation of MYC and BCL2 is one of the important pathogenic mechanisms. Thus, combined targeting of MYC and BCL2 appears to be a promising strategy. Dihydroorotate dehydrogenase (DHODH) is the fourth rate-limiting enzyme for the de novo biosynthesis of pyrimidine. It has been shown to be a potential therapeutic target for multiple diseases. In this study, the DHODH inhibitor brequinar exhibited growth inhibition, cell cycle blockade, and apoptosis promotion in HGBCL cell lines with MYC and BCL2 rearrangements. The combination of brequinar and BCL2 inhibitors venetoclax had a synergistic inhibitory effect on the survival of DHL cells through different pathways. Venetoclax could upregulate MCL-1 and MYC expression, which has been reported as a resistance mechanism of BCL2 inhibitors. Brequinar downregulated MCL-1 and MYC, which could potentially overcome drug resistance to venetoclax in HGBCL cells. Furthermore, brequinar could downregulate a broad range of genes, including ribosome biosynthesis genes, which might contribute to its anti-tumor effects. In vivo studies demonstrated synergetic tumor growth inhibition in xenograft models with brequinar and venetoclax combination treatment. These results provide preliminary evidence for the rational combination of DHODH and BCL2 blockade in HGBCL with abnormal MYC and BCL2.<\/jats:p>","DOI":"10.1186\/s12885-024-12534-w","type":"journal-article","created":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T07:02:20Z","timestamp":1719298940000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Targeted inhibition of DHODH is synergistic with BCL2 blockade in HGBCL with concurrent MYC and BCL2 rearrangement"],"prefix":"10.1186","volume":"24","author":[{"given":"Lin","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbin","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,25]]},"reference":[{"key":"12534_CR1","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1002\/ajh.25460","volume":"94 5","author":"Y Liu","year":"2019","unstructured":"Liu Y, Barta SK. Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2019;94 5:604\u201316. https:\/\/doi.org\/10.1002\/ajh.25460","journal-title":"Am J Hematol"},{"key":"12534_CR2","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1038\/s41571-019-0225-1","volume":"16 10","author":"Y Miao","year":"2019","unstructured":"Miao Y, Medeiros LJ, Li Y, Li J, Young KH. Genetic alterations and their clinical implications in DLBCL. Nat Rev Clin Oncol. 2019;16 10:634\u201352. https:\/\/doi.org\/10.1038\/s41571-019-0225-1","journal-title":"Nat Rev Clin Oncol"},{"key":"12534_CR3","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1182\/blood-2016-02-636316","volume":"129 3","author":"P Sesques","year":"2017","unstructured":"Sesques P, Johnson NA. Approach to the diagnosis and treatment of high-grade B-cell lymphomas with MYC and BCL2 and\/or BCL6 rearrangements. Blood. 2017;129 3:280\u20138. https:\/\/doi.org\/10.1182\/blood-2016-02-636316","journal-title":"Blood"},{"key":"12534_CR4","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.beha.2018.07.012","volume":"31 3","author":"B Merron","year":"2018","unstructured":"Merron B, Davies A. Double hit lymphoma: how do we define it and how do we treat it? Best Pract Res Clin Haematol. 2018;31 3:233\u201340. https:\/\/doi.org\/10.1016\/j.beha.2018.07.012","journal-title":"Best Pract Res Clin Haematol"},{"key":"12534_CR5","doi-asserted-by":"publisher","first-page":"4622","DOI":"10.1002\/cncr.31646","volume":"124 24","author":"PA Riedell","year":"2018","unstructured":"Riedell PA, Smith SM. Double hit and double expressors in lymphoma: definition and treatment. Cancer. 2018;124 24:4622\u201332. https:\/\/doi.org\/10.1002\/cncr.31646","journal-title":"Cancer"},{"key":"12534_CR6","doi-asserted-by":"publisher","unstructured":"Phuoc V, Sandoval-Sus J, Chavez JC. Drug therapy for double-hit lymphoma. Drugs Context. 2019;8. https:\/\/doi.org\/10.7573\/dic.2019-8-1","DOI":"10.7573\/dic.2019-8-1"},{"key":"12534_CR7","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13045-018-0608-2","volume":"11 1","author":"GF Perini","year":"2018","unstructured":"Perini GF, Ribeiro GN, Pinto Neto JV, Campos LT, Hamerschlak N. BCL-2 as therapeutic target for hematological malignancies. J Hematol Oncol. 2018;11 1:65. https:\/\/doi.org\/10.1186\/s13045-018-0608-2","journal-title":"J Hematol Oncol"},{"key":"12534_CR8","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1007\/s40265-019-01163-4","volume":"79 12","author":"FF Yalniz","year":"2019","unstructured":"Yalniz FF, Wierda WG. Targeting BCL2 in chronic lymphocytic leukemia and other hematologic malignancies. Drugs. 2019;79 12:1287\u2013304. https:\/\/doi.org\/10.1007\/s40265-019-01163-4","journal-title":"Drugs"},{"key":"12534_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1182\/hematology.2020000154","volume":"2020 1","author":"AW Roberts","year":"2020","unstructured":"Roberts AW. Therapeutic development and current uses of BCL-2 inhibition. Hematol Am Soc Hematol Educ Program. 2020;2020 1:1\u20139. https:\/\/doi.org\/10.1182\/hematology.2020000154","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"12534_CR10","doi-asserted-by":"publisher","first-page":"3967","DOI":"10.1158\/1078-0432.CCR-17-3004","volume":"24 16","author":"LV Pham","year":"2018","unstructured":"Pham LV, Huang S, Zhang H, Zhang J, Bell T, Zhou S, et al. Strategic Therapeutic Targeting to overcome Venetoclax Resistance in Aggressive B-cell lymphomas. Clin Cancer Res. 2018;24 16:3967\u201380. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-3004","journal-title":"Clin Cancer Res"},{"key":"12534_CR11","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","volume":"35 8","author":"MS Davids","year":"2017","unstructured":"Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG, et al. Phase I first-in-human study of Venetoclax in patients with relapsed or refractory Non-hodgkin Lymphoma. J Clin Oncol. 2017;35 8:826\u201333. https:\/\/doi.org\/10.1200\/JCO.2016.70.4320","journal-title":"J Clin Oncol"},{"issue":"1","key":"12534_CR12","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1158\/1078-0432.CCR-13-3346","volume":"21","author":"SE Trabucco","year":"2015","unstructured":"Trabucco SE, Gerstein RM, Evens AM, Bradner JE, Shultz LD, Greiner DL, et al. Inhibition of bromodomain proteins for the treatment of human diffuse large B-cell lymphoma. Clin Cancer Res. 2015;21(1):113\u201322. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-3346","journal-title":"Clin Cancer Res"},{"key":"12534_CR13","doi-asserted-by":"publisher","unstructured":"Li W, Gupta SK, Han W, Kundson RA, Nelson S, Knutson D, et al. Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and\/or BCL6 rearrangements with epigenetic bromodomain inhibitors. J Hematol Oncol. 2019;12(1:73). https:\/\/doi.org\/10.1186\/s13045-019-0761-2","DOI":"10.1186\/s13045-019-0761-2"},{"key":"12534_CR14","doi-asserted-by":"publisher","first-page":"107631","DOI":"10.1016\/j.pharmthera.2020.107631","volume":"215","author":"F Spriano","year":"2020","unstructured":"Spriano F, Stathis A, Bertoni F. Targeting BET bromodomain proteins in cancer: the example of lymphomas. Pharmacol Ther. 2020;215:107631. https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107631","journal-title":"Pharmacol Ther"},{"key":"12534_CR15","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.pharmthera.2018.10.012","volume":"195","author":"JT Madak","year":"2019","unstructured":"Madak JT, Bankhead A 3rd, Cuthbertson CR, Showalter HD, Neamati N. Revisiting the role of dihydroorotate dehydrogenase as a therapeutic target for cancer. Pharmacol Ther. 2019;195:111\u201331. https:\/\/doi.org\/10.1016\/j.pharmthera.2018.10.012","journal-title":"Pharmacol Ther"},{"key":"12534_CR16","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25 4","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25 4:402\u20138. https:\/\/doi.org\/10.1006\/meth.2001.1262","journal-title":"Methods"},{"key":"12534_CR17","doi-asserted-by":"publisher","first-page":"3316","DOI":"10.1182\/bloodadvances.2020002231","volume":"4 14","author":"TEC Cummin","year":"2020","unstructured":"Cummin TEC, Cox KL, Murray TD, Turaj AH, Dunning L, English VL, et al. BET inhibitors synergize with venetoclax to induce apoptosis in MYC-driven lymphomas with high BCL-2 expression. Blood Adv. 2020;4 14:3316\u201328. https:\/\/doi.org\/10.1182\/bloodadvances.2020002231","journal-title":"Blood Adv"},{"key":"12534_CR18","doi-asserted-by":"publisher","first-page":"26494","DOI":"10.18632\/oncotarget.4764","volume":"6 28","author":"Y Quan","year":"2015","unstructured":"Quan Y, Wang N, Chen Q, Xu J, Cheng W, Di M, et al. SIRT3 inhibits prostate cancer by destabilizing oncoprotein c-MYC through regulation of the PI3K\/Akt pathway. Oncotarget. 2015;6 28:26494\u2013507. https:\/\/doi.org\/10.18632\/oncotarget.4764","journal-title":"Oncotarget"},{"key":"12534_CR19","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1073\/pnas.1818539116","volume":"116 6","author":"XJ Chen","year":"2019","unstructured":"Chen XJ, Zhang WN, Chen B, Xi WD, Lu Y, Huang JY, et al. Homoharringtonine deregulates MYC transcriptional expression by directly binding NF-kappaB repressing factor. Proc Natl Acad Sci U S A. 2019;116 6:2220\u20135. https:\/\/doi.org\/10.1073\/pnas.1818539116","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"12534_CR20","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/cr.2017.146","volume":"28","author":"L Huang","year":"2018","unstructured":"Huang L, Liu D, Wang N, Ling S, Tang Y, Wu J, et al. Integrated genomic analysis identifies deregulated JAK\/STAT-MYC-biosynthesis axis in aggressive NK-cell leukemia. Cell Res. 2018;28(2):172\u201386. https:\/\/doi.org\/10.1038\/cr.2017.146","journal-title":"Cell Res"},{"key":"12534_CR21","doi-asserted-by":"publisher","unstructured":"Kapoor I, Bodo J, Hill BT, Hsi ED, Almasan A, Targeting. BCL-2 in B-cell malignancies and overcoming therapeutic resistance. Cell Death Dis. 2020;11 11:941. https:\/\/doi.org\/10.1038\/s41419-020-03144-y","DOI":"10.1038\/s41419-020-03144-y"},{"key":"12534_CR22","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1080\/10428194.2019.1660974","volume":"61 2","author":"P Blombery","year":"2020","unstructured":"Blombery P. Mechanisms of intrinsic and acquired resistance to venetoclax in B-cell lymphoproliferative disease. Leuk Lymphoma. 2020;61 2:257\u201362. https:\/\/doi.org\/10.1080\/10428194.2019.1660974","journal-title":"Leuk Lymphoma"},{"key":"12534_CR23","doi-asserted-by":"publisher","first-page":"81593","DOI":"10.4161\/cc.20008","volume":"11","author":"WL Labisso","year":"2012","unstructured":"Labisso WL, Wirth M, Stojanovic N, Stauber RH, Schnieke A, Schmid RM, et al. MYC directs transcription of MCL1 and eIF4E genes to control sensitivity of gastric cancer cells toward HDAC inhibitors. Cell Cycle. 2012;11:81593\u2013602. https:\/\/doi.org\/10.4161\/cc.20008","journal-title":"Cell Cycle"},{"key":"12534_CR24","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/j.tranon.2018.07.007","volume":"11 5","author":"W Deng","year":"2018","unstructured":"Deng W, Clipson A, Liu H, Huang Y, Dobson R, Wang M, et al. Variable responses of MYC Translocation Positive Lymphoma Cell Lines to different combinations of Novel agents: impact of BCL2 family protein expression. Transl Oncol. 2018;11 5:1147\u201354. https:\/\/doi.org\/10.1016\/j.tranon.2018.07.007","journal-title":"Transl Oncol"},{"key":"12534_CR25","doi-asserted-by":"publisher","unstructured":"Destefanis F, Manara V, Bellosta P. Myc as a Regulator of Ribosome Biogenesis and Cell Competition: a link to Cancer. Int J Mol Sci. 2020;21(11). https:\/\/doi.org\/10.3390\/ijms21114037","DOI":"10.3390\/ijms21114037"},{"key":"12534_CR26","doi-asserted-by":"publisher","unstructured":"Sykes DB, Kfoury YS, Mercier FE, Wawer MJ, Law JM, Haynes MK, et al. Inhibition of Dihydroorotate Dehydrogenase overcomes differentiation blockade in Acute myeloid leukemia. Cell. 2016;167. https:\/\/doi.org\/10.1016\/j.cell.2016.08.057. 1:171\u2009\u2013\u200986 e15.","DOI":"10.1016\/j.cell.2016.08.057"},{"key":"12534_CR27","doi-asserted-by":"publisher","first-page":"e838","DOI":"10.1016\/S2352-3026(20)30222-2","volume":"7 11","author":"JK Lue","year":"2020","unstructured":"Lue JK, O\u2019Connor OA. A perspective on improving the R-CHOP regimen: from Mega-CHOP to ROBUST R-CHOP, the PHOENIX is yet to rise. Lancet Haematol. 2020;7 11:e838\u201350. https:\/\/doi.org\/10.1016\/S2352-3026(20)30222-2","journal-title":"Lancet Haematol"},{"key":"12534_CR28","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1080\/13543784.2021.1855140","volume":"30 1","author":"A Patriarca","year":"2021","unstructured":"Patriarca A, Gaidano G. Investigational drugs for the treatment of diffuse large B-cell lymphoma. Expert Opin Investig Drugs. 2021;30 1:25\u201338. https:\/\/doi.org\/10.1080\/13543784.2021.1855140","journal-title":"Expert Opin Investig Drugs"},{"key":"12534_CR29","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.cell.2012.03.003","volume":"149 1","author":"CV Dang","year":"2012","unstructured":"Dang CV. MYC on the path to cancer. Cell. 2012;149 1:22\u201335. https:\/\/doi.org\/10.1016\/j.cell.2012.03.003","journal-title":"Cell"},{"key":"12534_CR30","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1038\/nrc2231","volume":"8 12","author":"N Meyer","year":"2008","unstructured":"Meyer N, Penn LZ. Reflecting on 25 years with MYC. Nat Rev Cancer. 2008;8 12:976\u201390. https:\/\/doi.org\/10.1038\/nrc2231","journal-title":"Nat Rev Cancer"},{"key":"12534_CR31","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1038\/s41375-019-0461-5","volume":"33 10","author":"S Christian","year":"2019","unstructured":"Christian S, Merz C, Evans L, Gradl S, Seidel H, Friberg A, et al. The novel dihydroorotate dehydrogenase (DHODH) inhibitor BAY 2402234 triggers differentiation and is effective in the treatment of myeloid malignancies. Leukemia. 2019;33 10:2403\u201315. https:\/\/doi.org\/10.1038\/s41375-019-0461-5","journal-title":"Leukemia"},{"key":"12534_CR32","doi-asserted-by":"publisher","first-page":"3086","DOI":"10.7150\/jca.14835","volume":"8 15","author":"MS Dorasamy","year":"2017","unstructured":"Dorasamy MS, Choudhary B, Nellore K, Subramanya H, Wong PF. Dihydroorotate dehydrogenase inhibitors target c-Myc and Arrest Melanoma, Myeloma and Lymphoma cells at S-phase. J Cancer. 2017;8 15:3086\u201398. https:\/\/doi.org\/10.7150\/jca.14835","journal-title":"J Cancer"},{"key":"12534_CR33","doi-asserted-by":"publisher","first-page":"163","DOI":"10.33549\/physiolres.932355","volume":"62 2","author":"W Dudzinska","year":"2013","unstructured":"Dudzinska W, Lubkowska A, Jakubowska K, Suska M, Skotnicka E. Insulin resistance induced by maximal exercise correlates with a post-exercise increase in uridine concentration in the blood of healthy young men. Physiol Res. 2013;62 2:163\u201370. https:\/\/doi.org\/10.33549\/physiolres.932355","journal-title":"Physiol Res"},{"key":"12534_CR34","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/cdd.2017.186","volume":"25 1","author":"J Kale","year":"2018","unstructured":"Kale J, Osterlund EJ, Andrews DW. BCL-2 family proteins: changing partners in the dance towards death. Cell Death Differ. 2018;25 1:65\u201380. https:\/\/doi.org\/10.1038\/cdd.2017.186","journal-title":"Cell Death Differ"},{"key":"12534_CR35","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.3324\/haematol.2018.204958","volume":"104 7","author":"A Uchida","year":"2019","unstructured":"Uchida A, Isobe Y, Asano J, Uemura Y, Hoshikawa M, Takagi M, et al. Targeting BCL2 with venetoclax is a promising therapeutic strategy for double-proteinexpression lymphoma with MYC and BCL2 rearrangements. Haematologica. 2019;104 7:1417\u201321. https:\/\/doi.org\/10.3324\/haematol.2018.204958","journal-title":"Haematologica"},{"key":"12534_CR36","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1182\/blood.2020006578","volume":"137 5","author":"F Morschhauser","year":"2021","unstructured":"Morschhauser F, Feugier P, Flinn IW, Gasiorowski R, Greil R, Illes A, et al. A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma. Blood. 2021;137 5:600\u20139. https:\/\/doi.org\/10.1182\/blood.2020006578","journal-title":"Blood"},{"key":"12534_CR37","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1182\/blood-2018-11-880526","volume":"133 18","author":"AD Zelenetz","year":"2019","unstructured":"Zelenetz AD, Salles G, Mason KD, Casulo C, Le Gouill S, Sehn LH, et al. Venetoclax plus R- or G-CHOP in non-hodgkin lymphoma: results from the CAVALLI phase 1b trial. Blood. 2019;133 18:1964\u201376. https:\/\/doi.org\/10.1182\/blood-2018-11-880526","journal-title":"Blood"},{"key":"12534_CR38","doi-asserted-by":"publisher","first-page":"793","DOI":"10.7150\/jca.17766","volume":"8 5","author":"JH Wang","year":"2017","unstructured":"Wang JH, Bi XW, Li PF, Xia ZJ, Huang HQ, Jiang WQ, et al. Overexpression of MYC and BCL2 predicts poor prognosis in patients with Extranodal NK\/T-cell lymphoma, nasal type. J Cancer. 2017;8 5:793\u2013800. https:\/\/doi.org\/10.7150\/jca.17766","journal-title":"J Cancer"},{"key":"12534_CR39","doi-asserted-by":"publisher","first-page":"7091718","DOI":"10.1155\/2020\/7091718","volume":"2020","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Guo S, Xie C, Fang J. Uridine Metabolism and its role in glucose, lipid, and amino acid homeostasis. Biomed Res Int. 2020;2020:7091718. https:\/\/doi.org\/10.1155\/2020\/7091718","journal-title":"Biomed Res Int"},{"key":"12534_CR40","doi-asserted-by":"publisher","unstructured":"Lee KM, Giltnane JM, Balko JM, Schwarz LJ, Guerrero-Zotano AL, Hutchinson KE et al. MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation. Cell Metab. 2017;26 4:633\u2009\u2013\u200947 e7; https:\/\/doi.org\/10.1016\/j.cmet.2017.09.009","DOI":"10.1016\/j.cmet.2017.09.009"},{"key":"12534_CR41","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1182\/blood.2019003535","volume":"135 20","author":"SE Lacy","year":"2020","unstructured":"Lacy SE, Barrans SL, Beer PA, Painter D, Smith AG, Roman E, et al. Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report. Blood. 2020;135 20:1759\u201371. https:\/\/doi.org\/10.1182\/blood.2019003535","journal-title":"Blood"},{"key":"12534_CR42","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","volume":"378 15","author":"R Schmitz","year":"2018","unstructured":"Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, et al. Genetics and Pathogenesis of diffuse large B-Cell lymphoma. N Engl J Med. 2018;378 15:1396\u2013407. https:\/\/doi.org\/10.1056\/NEJMoa1801445","journal-title":"N Engl J Med"},{"key":"12534_CR43","doi-asserted-by":"publisher","first-page":"e101801","DOI":"10.15252\/embj.2019101801","volume":"38 18","author":"MC Lanz","year":"2019","unstructured":"Lanz MC, Dibitetto D, Smolka MB. DNA damage kinase signaling: checkpoint and repair at 30 years. EMBO J. 2019;38 18:e101801. https:\/\/doi.org\/10.15252\/embj.2019101801","journal-title":"EMBO J"},{"key":"12534_CR44","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1097\/00007890-199602270-00020","volume":"61 4","author":"KF Siemasko","year":"1996","unstructured":"Siemasko KF, Chong AS, Williams JW, Bremer EG, Finnegan A. Regulation of B cell function by the immunosuppressive agent leflunomide. Transplantation. 1996;61 4:635\u201342. https:\/\/doi.org\/10.1097\/00007890-199602270-00020","journal-title":"Transplantation"},{"key":"12534_CR45","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/nrc.2017.104","volume":"18 1","author":"J Pelletier","year":"2018","unstructured":"Pelletier J, Thomas G, Volarevic S. Ribosome biogenesis in cancer: new players and therapeutic avenues. Nat Rev Cancer. 2018;18 1:51\u201363. https:\/\/doi.org\/10.1038\/nrc.2017.104","journal-title":"Nat Rev Cancer"},{"key":"12534_CR46","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/nrc2819","volume":"10 4","author":"J van Riggelen","year":"2010","unstructured":"van Riggelen J, Yetil A, Felsher DW. MYC as a regulator of ribosome biogenesis and protein synthesis. Nat Rev Cancer. 2010;10 4:301\u20139. https:\/\/doi.org\/10.1038\/nrc2819","journal-title":"Nat Rev Cancer"},{"key":"12534_CR47","doi-asserted-by":"publisher","first-page":"4348","DOI":"10.1158\/0008-5472.CAN-18-2718","volume":"79 17","author":"C Morcelle","year":"2019","unstructured":"Morcelle C, Menoyo S, Moron-Duran FD, Tauler A, Kozma SC, Thomas G, et al. Oncogenic MYC induces the impaired ribosome Biogenesis Checkpoint and stabilizes p53 Independent of increased ribosome content. Cancer Res. 2019;79 17:4348\u201359. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-2718","journal-title":"Cancer Res"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12534-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-12534-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12534-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T07:04:29Z","timestamp":1719299069000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-12534-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,25]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["12534"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-12534-w","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,25]]},"assertion":[{"value":"27 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all participants. All in vivo studies were conducted according to the China Medical University Animal Care and Use Committee guidelines and approved by the Institutional Review Board of The First Hospital of China Medical University (CMUXN2021735,CMUXN2023024). All methods, including animals, were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing or conflicting interests, financial or otherwise.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"761"}}